Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 26 entries
Sorted by: Best Match Show Resources per page
GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent.

Clinical case reports

Winkler A, Kietz S, Bahlmann H, Jafarzade G, Lode HN, Heckmann M.
PMID: 27525093
Clin Case Rep. 2016 Jul 20;4(8):816-9. doi: 10.1002/ccr3.616. eCollection 2016 Aug.

This case report describes the successful use of granulocyte and macrophage colony-stimulating factor as salvage therapy and an alternative to hematopoietic stem cell transplantation in a 14-year-old adolescent with metamizole (dipyrone)-induced agranulocytosis and severe septic shock.

Cite
Winkler A, Kietz S, Bahlmann H, et al. GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent. Clin Case Rep. 2016;4(8):816-9doi: 10.1002/ccr3.616.
Winkler, A., Kietz, S., Bahlmann, H., Jafarzade, G., Lode, H. N., & Heckmann, M. (2016). GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent. Clinical case reports, 4(8), 816-9. https://doi.org/10.1002/ccr3.616
Winkler, Annegret, et al. "GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent." Clinical case reports vol. 4,8 (2016): 816-9. doi: https://doi.org/10.1002/ccr3.616
Winkler A, Kietz S, Bahlmann H, Jafarzade G, Lode HN, Heckmann M. GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent. Clin Case Rep. 2016 Jul 20;4(8):816-9. doi: 10.1002/ccr3.616. eCollection 2016 Aug. PMID: 27525093; PMCID: PMC4974437.
Copy Download .nbib Format: NLM
Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis.

Clinical nephrology. Case studies

Sewaralthahab K, Rennke H, Sewaralthahab S, Madias NE, Jaber BL.
PMID: 29043131
Clin Nephrol Case Stud. 2014 Dec 15;3:31-36. doi: 10.5414/CNCS108420. eCollection 2015.

We present the case of a 43-year-old woman with a diagnosis of pulmonary alveolar proteinosis, on chronic treatment with sargramostim, a recombinant granulocyte-macrophage colony-stimulating factor, who presented with the nephrotic syndrome secondary to biopsy-proven membranous nephropathy. We discuss potential...

Cite
Sewaralthahab K, Rennke H, Sewaralthahab S, et al. Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis. Clin Nephrol Case Stud. 2014;3:31-36doi: 10.5414/CNCS108420.
Sewaralthahab, K., Rennke, H., Sewaralthahab, S., Madias, N. E., & Jaber, B. L. (2015). Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis. Clinical nephrology. Case studies, 331-36. https://doi.org/10.5414/CNCS108420
Sewaralthahab, Kamal, et al. "Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis." Clinical nephrology. Case studies vol. 3 (2015): 31-36. doi: https://doi.org/10.5414/CNCS108420
Sewaralthahab K, Rennke H, Sewaralthahab S, Madias NE, Jaber BL. Potential association between membranous nephropathy and sargramostim therapy for pulmonary alveolar proteinosis. Clin Nephrol Case Stud. 2014 Dec 15;3:31-36. doi: 10.5414/CNCS108420. eCollection 2015. PMID: 29043131; PMCID: PMC5437997.
Copy Download .nbib Format: NLM
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Journal for immunotherapy of cancer

Martinez Sanz P, van Rees DJ, van Zogchel LMJ, Klein B, Bouti P, Olsman H, Schornagel K, Kok I, Sunak A, Leeuwenburg K, Timmerman I, Dierselhuis MP, Kholosy WM, Molenaar JJ, van Bruggen R, van den Berg TK, Kuijpers TW, Matlung HL, Tytgat GAM, Franke K.
PMID: 34049929
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002259.

BACKGROUND: Current immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibody-dependent cellular cytotoxicity (ADCC), a process mediated by...

Cite
Martinez Sanz P, van Rees DJ, van Zogchel LMJ, et al. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. J Immunother Cancer. 2021;9(5)doi: 10.1136/jitc-2020-002259.
Martinez Sanz, P., van Rees, D. J., van Zogchel, L. M. J., Klein, B., Bouti, P., Olsman, H., Schornagel, K., Kok, I., Sunak, A., Leeuwenburg, K., Timmerman, I., Dierselhuis, M. P., Kholosy, W. M., Molenaar, J. J., van Bruggen, R., van den Berg, T. K., Kuijpers, T. W., Matlung, H. L., Tytgat, G. A. M., & Franke, K. (2021). G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. Journal for immunotherapy of cancer, 9(5), . https://doi.org/10.1136/jitc-2020-002259
Martinez Sanz, Paula, et al. "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment." Journal for immunotherapy of cancer vol. 9,5 (2021). doi: https://doi.org/10.1136/jitc-2020-002259
Martinez Sanz P, van Rees DJ, van Zogchel LMJ, Klein B, Bouti P, Olsman H, Schornagel K, Kok I, Sunak A, Leeuwenburg K, Timmerman I, Dierselhuis MP, Kholosy WM, Molenaar JJ, van Bruggen R, van den Berg TK, Kuijpers TW, Matlung HL, Tytgat GAM, Franke K. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002259. PMID: 34049929; PMCID: PMC8166600.
Copy Download .nbib Format: NLM
Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model.

International journal of radiation biology

Zhong Y, Pouliot M, Downey AM, Mockbee C, Roychowdhury D, Wierzbicki W, Authier S.
PMID: 32960660
Int J Radiat Biol. 2020 Sep 22;1-17. doi: 10.1080/09553002.2019.1673499. Epub 2020 Sep 22.

BACKGROUND: High dose ionizing radiation exposure is associated with myelo-depression leading to pancytopenia and the expected clinical manifestations of acute radiation syndrome (ARS). Herein, we evaluated the efficacy of sargramostim (LeukineMETHODS: A randomized and blinded nonhuman primate (NHP) study...

Cite
Zhong Y, Pouliot M, Downey AM, et al. Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. Int J Radiat Biol. 2020;1-17doi: 10.1080/09553002.2019.1673499.
Zhong, Y., Pouliot, M., Downey, A. M., Mockbee, C., Roychowdhury, D., Wierzbicki, W., & Authier, S. (2020). Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. International journal of radiation biology, 1-17. https://doi.org/10.1080/09553002.2019.1673499
Zhong, Yifei, et al. "Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model." International journal of radiation biology vol. (2020): 1-17. doi: https://doi.org/10.1080/09553002.2019.1673499
Zhong Y, Pouliot M, Downey AM, Mockbee C, Roychowdhury D, Wierzbicki W, Authier S. Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model. Int J Radiat Biol. 2020 Sep 22;1-17. doi: 10.1080/09553002.2019.1673499. Epub 2020 Sep 22. PMID: 32960660.
Copy Download .nbib Format: NLM
Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)

Potter H, Woodcock JH, Boyd TD, Coughlan CM, O'Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, Adame V, Anton P, Chial HJ, Gray H, Daniels J, Stocker ME, Sillau SH.
PMID: 33778150
Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12158. doi: 10.1002/trc2.12158. eCollection 2021.

INTRODUCTION: Inflammatory markers have long been observed in the brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients, suggesting that inflammation contributes to AD and might be a therapeutic target. However, non-steroidal anti-inflammatory drug trials in AD...

Cite
Potter H, Woodcock JH, Boyd TD, et al. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2021;7(1):e12158doi: 10.1002/trc2.12158.
Potter, H., Woodcock, J. H., Boyd, T. D., Coughlan, C. M., O'Shaughnessy, J. R., Borges, M. T., Thaker, A. A., Raj, B. A., Adamszuk, K., Scott, D., Adame, V., Anton, P., Chial, H. J., Gray, H., Daniels, J., Stocker, M. E., & Sillau, S. H. (2021). Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.), 7(1), e12158. https://doi.org/10.1002/trc2.12158
Potter, Huntington, et al. "Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease." Alzheimer's & dementia (New York, N. Y.) vol. 7,1 (2021): e12158. doi: https://doi.org/10.1002/trc2.12158
Potter H, Woodcock JH, Boyd TD, Coughlan CM, O'Shaughnessy JR, Borges MT, Thaker AA, Raj BA, Adamszuk K, Scott D, Adame V, Anton P, Chial HJ, Gray H, Daniels J, Stocker ME, Sillau SH. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12158. doi: 10.1002/trc2.12158. eCollection 2021. PMID: 33778150; PMCID: PMC7988877.
Copy Download .nbib Format: NLM
Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development.

3 Biotech

Mishra K, Alsbeih G.
PMID: 28868219
3 Biotech. 2017 Oct;7(5):292. doi: 10.1007/s13205-017-0925-0. Epub 2017 Aug 29.

The search for efficient radioprotective agents to protect from radiation-induced toxicity, due to planned or accidental radiation exposure, is still ongoing worldwide. Despite decades of research and development of widely different biochemical classes of natural and derivative compounds, a...

Cite
Mishra K, Alsbeih G. Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development. 3 Biotech. 2017;7(5):292doi: 10.1007/s13205-017-0925-0.
Mishra, K., & Alsbeih, G. (2017). Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development. 3 Biotech, 7(5), 292. https://doi.org/10.1007/s13205-017-0925-0
Mishra, Krishnanand, and Alsbeih, Ghazi. "Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development." 3 Biotech vol. 7,5 (2017): 292. doi: https://doi.org/10.1007/s13205-017-0925-0
Mishra K, Alsbeih G. Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development. 3 Biotech. 2017 Oct;7(5):292. doi: 10.1007/s13205-017-0925-0. Epub 2017 Aug 29. PMID: 28868219; PMCID: PMC5574734.
Copy Download .nbib Format: NLM
Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies.

Cureus

Leary R, Gardner RB, Mockbee C, Roychowdhury DF.
PMID: 31157137
Cureus. 2019 Mar 19;11(3):e4276. doi: 10.7759/cureus.4276.

Drug development in oncology today routinely focuses on approaches that utilize the patients' immune system to destroy the malignancy. Combinatorial approaches of antineoplastic agents, both new and old, are being incorporated in the armamentarium of cancer treatments. The overarching...

Cite
Leary R, Gardner RB, Mockbee C, et al. Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cureus. 2019;11(3):e4276doi: 10.7759/cureus.4276.
Leary, R., Gardner, R. B., Mockbee, C., & Roychowdhury, D. F. (2019). Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cureus, 11(3), e4276. https://doi.org/10.7759/cureus.4276
Leary, Robyn, et al. "Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies." Cureus vol. 11,3 (2019): e4276. doi: https://doi.org/10.7759/cureus.4276
Leary R, Gardner RB, Mockbee C, Roychowdhury DF. Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cureus. 2019 Mar 19;11(3):e4276. doi: 10.7759/cureus.4276. PMID: 31157137; PMCID: PMC6529041.
Copy Download .nbib Format: NLM
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma.

Immunotherapy

Tarhini AA, Joshi I, Garner F.
PMID: 34157863
Immunotherapy. 2021 Aug;13(12):1011-1029. doi: 10.2217/imt-2021-0119. Epub 2021 Jun 23.

The use of immune checkpoint inhibitors in patients with metastatic melanoma generates clinical benefit, including improved survival. Yet disease resistance and immune-related adverse events persist as unmet needs. Sargramostim, a yeast-derived recombinant human GM-CSF, has shown clinical activity against...

Cite
Tarhini AA, Joshi I, Garner F. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy. 2021;13(12):1011-1029doi: 10.2217/imt-2021-0119.
Tarhini, A. A., Joshi, I., & Garner, F. (2021). Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy, 13(12), 1011-1029. https://doi.org/10.2217/imt-2021-0119
Tarhini, Ahmad A, et al. "Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma." Immunotherapy vol. 13,12 (2021): 1011-1029. doi: https://doi.org/10.2217/imt-2021-0119
Tarhini AA, Joshi I, Garner F. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy. 2021 Aug;13(12):1011-1029. doi: 10.2217/imt-2021-0119. Epub 2021 Jun 23. PMID: 34157863.
Copy Download .nbib Format: NLM
Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond.

International journal of radiation biology

Singh VK, Seed TM.
PMID: 34402734
Int J Radiat Biol. 2021;97(11):1526-1547. doi: 10.1080/09553002.2021.1969054. Epub 2021 Aug 31.

PURPOSE: The intent of this article is to report the status of some of the pharmaceuticals currently in late stage development for possible use for individuals unwantedly and acutely injured as a result of radiological/nuclear exposures. The two major...

Cite
Singh VK, Seed TM. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond. Int J Radiat Biol. 2021;97(11):1526-1547doi: 10.1080/09553002.2021.1969054.
Singh, V. K., & Seed, T. M. (2021). Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond. International journal of radiation biology, 97(11), 1526-1547. https://doi.org/10.1080/09553002.2021.1969054
Singh, Vijay K, and Seed, Thomas M. "Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond." International journal of radiation biology vol. 97,11 (2021): 1526-1547. doi: https://doi.org/10.1080/09553002.2021.1969054
Singh VK, Seed TM. Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond. Int J Radiat Biol. 2021;97(11):1526-1547. doi: 10.1080/09553002.2021.1969054. Epub 2021 Aug 31. PMID: 34402734.
Copy Download .nbib Format: NLM
Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance.

JIMD reports

Tanner LM, Kurko J, Tringham M, Aho H, Mykkänen J, Näntö-Salonen K, Niinikoski H, Lukkarinen H.
PMID: 27783330
JIMD Rep. 2017;34:97-104. doi: 10.1007/8904_2016_15. Epub 2016 Oct 26.

Pulmonary alveolar proteinosis (PAP) is a potentially fatal complication of lysinuric protein intolerance (LPI), an inherited disorder of cationic amino acid transport. The patients often present with mild respiratory symptoms, which may rapidly progress to acute respiratory failure responding...

Cite
Tanner LM, Kurko J, Tringham M, et al. Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance. JIMD Rep. 2016;34:97-104doi: 10.1007/8904_2016_15.
Tanner, L. M., Kurko, J., Tringham, M., Aho, H., Mykkänen, J., Näntö-Salonen, K., Niinikoski, H., & Lukkarinen, H. (2017). Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance. JIMD reports, 3497-104. https://doi.org/10.1007/8904_2016_15
Tanner, Laura M, et al. "Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance." JIMD reports vol. 34 (2017): 97-104. doi: https://doi.org/10.1007/8904_2016_15
Tanner LM, Kurko J, Tringham M, Aho H, Mykkänen J, Näntö-Salonen K, Niinikoski H, Lukkarinen H. Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance. JIMD Rep. 2017;34:97-104. doi: 10.1007/8904_2016_15. Epub 2016 Oct 26. PMID: 27783330; PMCID: PMC5509541.
Copy Download .nbib Format: NLM
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.

Pediatric blood & cancer

Mora J, Castañeda A, Gorostegui M, Santa-María V, Garraus M, Muñoz JP, Varo A, Perez-Jaume S, Mañe S.
PMID: 34022112
Pediatr Blood Cancer. 2021 Oct;68(10):e29121. doi: 10.1002/pbc.29121. Epub 2021 May 22.

BACKGROUND: Naxitamab is a humanized anti-disialoganglioside (GD2) monoclonal antibody approved for treatment of bone/bone marrow refractory high-risk neuroblastoma (HR-NB). Compassionate use (CU) expanded access program at Hospital Sant Joan de Deu permitted treatment of patients in complete remission (CR)....

Cite
Mora J, Castañeda A, Gorostegui M, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021;68(10):e29121doi: 10.1002/pbc.29121.
Mora, J., Castañeda, A., Gorostegui, M., Santa-María, V., Garraus, M., Muñoz, J. P., Varo, A., Perez-Jaume, S., & Mañe, S. (2021). Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatric blood & cancer, 68(10), e29121. https://doi.org/10.1002/pbc.29121
Mora, Jaume, et al. "Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission." Pediatric blood & cancer vol. 68,10 (2021): e29121. doi: https://doi.org/10.1002/pbc.29121
Mora J, Castañeda A, Gorostegui M, Santa-María V, Garraus M, Muñoz JP, Varo A, Perez-Jaume S, Mañe S. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021 Oct;68(10):e29121. doi: 10.1002/pbc.29121. Epub 2021 May 22. PMID: 34022112.
Copy Download .nbib Format: NLM
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.

Leukemia research

Webster JA, Robinson TM, Blackford AL, Warlick E, Ferguson A, Borrello I, Zahurak M, Jones RJ, Smith BD.
PMID: 34768161
Leuk Res. 2021 Dec;111:106737. doi: 10.1016/j.leukres.2021.106737. Epub 2021 Nov 02.

PURPOSE: Chronic myeloid leukemia (CP-CML) patients can achieve undetectable minimal residual disease (UMRD) and discontinue tyrosine kinase inhibitors (TKIs). Cellular immunity plays an important role in CML disease control. We conducted a randomized, non-blinded phase II trial of adjuvant...

Cite
Webster JA, Robinson TM, Blackford AL, et al. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leuk Res. 2021;111:106737doi: 10.1016/j.leukres.2021.106737.
Webster, J. A., Robinson, T. M., Blackford, A. L., Warlick, E., Ferguson, A., Borrello, I., Zahurak, M., Jones, R. J., & Smith, B. D. (2021). A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leukemia research, 111106737. https://doi.org/10.1016/j.leukres.2021.106737
Webster, Jonathan A, et al. "A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML." Leukemia research vol. 111 (2021): 106737. doi: https://doi.org/10.1016/j.leukres.2021.106737
Webster JA, Robinson TM, Blackford AL, Warlick E, Ferguson A, Borrello I, Zahurak M, Jones RJ, Smith BD. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML. Leuk Res. 2021 Dec;111:106737. doi: 10.1016/j.leukres.2021.106737. Epub 2021 Nov 02. PMID: 34768161; PMCID: PMC8643330.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 26 entries